TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
1. TGTX reported Q1 earnings per share of 3 cents, missing expectations. 2. Sales reached $120.86 million, exceeding consensus of $118.43 million. 3. Briumvi's U.S. net sales were $119.7 million, reflecting strong market adoption. 4. Long-term projections for Briumvi revenue increased to $560 million for 2025. 5. Stock fell 13.2% despite positive sales growth and future forecasts.